Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL31076329 | 1.00 | PTGS1 (0.56) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| Water SCHEMBL1614966 | 1.00 | PTGS1 (0.56) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL2622 | 0.95 | PTGS1 (0.60) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL21777928 | 0.95 | PTGS1 (0.60) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| Hydrochloric Acid SCHEMBL14053301 | 0.91 | PTGS1 (0.56) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL2524419 | 0.91 | PTGS1 (0.56) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL11359486 | 0.91 | PTGS1 (0.56) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL2288880 | 0.91 | PTGS1 (0.56) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL2521154 | 0.91 | PTGS1 (0.56) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL20607658 | 0.91 | PTGS1 (0.56) | PTGS1PDE4ALMNASLC6A6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115385871-A | Shuxinding salt | 沪亚生物国际有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-110312720-A | The inhibitor of bruton's tyrosine kinase | 吉利德科学公司 | 2019-10-08 | — | — | CN | claimed |
| US-10370381-B2 | Inhibitors of bruton'S tyrosine kinase | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | claimed |
| EP-3170829-B1 | NOVEL SALT OF TENOFOVIR DISOPROXIL | JW PHARMACEUTICAL CORP (KR) | 2018-09-19 | — | — | EP | claimed |
| US-20180251464-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | GILEAD SCIENCES, INC. | 2018-09-06 | — | — | US | claimed |
| WO-2018156895-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | GILEAD SCIENCES, INC. (US) | 2018-08-30 | — | — | WO | claimed |
| US-9879038-B2 | Salt of tenofovir disoproxil | JW PHARMACEUTICAL CORPORATION (KR) | 2018-01-30 | — | — | US | claimed |
| US-20170152276-A1 | NOVEL SALT OF TENOFOVIR DISOPROXIL | JW PHARMACEUTICAL CORPORATION (KR) | 2017-06-01 | — | — | US | claimed |
| CN-106795187-A | new tenofovir salt | JW制药公司 | 2017-05-31 | — | — | CN | claimed |
| EP-3170829-A1 | NOVEL SALT OF TENOFOVIR DISOPROXIL | JW Pharmaceutical Corporation (KR) | 2017-05-24 | — | — | EP | claimed |
| EP-4731628-A1 | CRYSTALLINE SALTS OF LINSITINIB FOR TREATING THYROID EYE DISEASE | Sling Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260092037-A1 | CRYSTALLINE SALT FORMS OF N-((1-(2-(TERT-BUTYLAMINO)-2-OXOETHYL)PIPERIDIN-4-YL) METHYL)-3-CHLORO-5-FLUOROBENZAMIDE AND METHODS OF USE THEREOF | PRAXIS PREC MEDICINES INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12528932-B2 | Composite comprising a reinforcing element and a rubber composition | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2026-01-20 | — | — | US | disclosed |
| EP-4673219-A1 | CRYSTALLINE SALT FORMS OF N-((1-(2-(TERT-BUTYLAMINO)-2-OXOETHYL)PIPERIDIN-4-YL)METHYL)-3-CHLORO-5-FLUOROBENZAMIDE AND METHODS OF USE THEREOF | Praxis Precision Medicines, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-2025121965-A1 | NOVEL CRYSTAL FORM OF TEGOPRAZAN SULFONIC ACID SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2025-06-12 | — | — | WO | disclosed |
| EP-1000048-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | Astra Aktiebolag (SE) | 2000-05-17 | — | — | EP | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
| WO-1999005134-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1999-02-04 | — | — | WO | disclosed |
| US-5006570-A | Dihydrobenzofuran- and chroman-carboxamide derivatives, processes for the preparation thereof and use thereof as neuroleptics | LABORATOIRES DELAGRANGE (FR) | 1991-04-09 | — | — | US | disclosed |
| US-3960870-A | Alkanesulfonic acid salts of decinine | SMITHKLINE CORPORATION (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152276-A1 | NOVEL SALT OF TENOFOVIR DISOPROXIL | SLC28A1, SLC5A1, SLC20A1 | PTGS1 1244/4885PDE4A 323/4885LMNA 4101/4885 |
| US-12528932-B2 | Composite comprising a reinforcing element and a rubber composition | COL1A1, TERB1, H1-0 | PTGS1 267/4885PDE4A 4871/4885LMNA 1972/4885 |
| US-20260092037-A1 | CRYSTALLINE SALT FORMS OF N-((1-(2-(TERT-BUTYLAMINO)-2-OXOETHYL)PIPERIDIN-4-YL) METHYL)-3-CHLORO-5-FLUOROBENZAMIDE AND METHODS OF USE THEREOF | SLC25A11, SLC16A1, GRIK1 | PTGS1 436/4885PDE4A 4116/4885LMNA 3137/4885 |
| US-10370381-B2 | Inhibitors of bruton'S tyrosine kinase | ABL1, BTK, ABL2 | PTGS1 3146/4885PDE4A 1052/4885LMNA 1267/4885 |
| US-20180251464-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | PTGS1 3146/4885PDE4A 1052/4885LMNA 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.